# Cancer Cachexia Market

> Cancer Cachexia Market Research Report: Size, Share, Trend Analysis By Therapy Type (Pharmacological, Nutritional Support, Physical Activity, Psychological Support), By Distribution Channel (Hospitals, Clinics, Online Pharmacies, Retail Pharmacies), By End Users (Hospitals, Homecare, Healthcare Institutions, Research Organizations) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 4.45%
- **2025:** USD 3.03 Billion
- **2035:** USD 4.68 Billion
- **Key Players:** Helsinn Healthcare, Pfizer Inc., Abbott Laboratories, Nestlé Health Science, Fresenius Kabi, Otsuka Holdings, Bristol Myers Squibb, Actimed Therapeutics

**Report ID:** MRFR/HC/10067-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Vikita Thakur · **Last Updated:** September 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/cancer-cachexia-market-11587

---

## Market Summary

## Cancer Cachexia Market Summary

The Cancer Cachexia Market was valued at USD 3.03 billion in 2025 and is projected to grow to USD 4.68 billion by 2035, expanding at a compound annual growth rate (CAGR) of 4.45% between 2026 and 2035. Market value is expected to reach USD 3.16 billion in 2026 as the first year of the forecast period. This growth is being driven primarily by sustained reimbursement in Japan and new U.S. regulatory guidance on approval endpoints, alongside a broader clinical shift toward biomarker-guided, mechanism-specific treatment.

Japan's Ministry of Health, Labour and Welfare has kept anamorelin reimbursed across five tumor indications since 2021, providing a stable, long-standing reimbursement precedent for cachexia therapies. At the same time, the U.S. Food and Drug Administration's (FDA) 2023 draft guidance on cancer-associated weight loss endpoints gave sponsors a workable approval path for the first time, removing a key regulatory barrier that had previously slowed drug development in this area.

Treatment practice is also moving away from decades of empirical dosing with megestrol acetate and dexamethasone. Clinicians are increasingly using growth differentiation factor 15 (GDF-15) and C-reactive protein panels to stratify patients, then adding tailored anabolic drugs to structured resistance training and nutritional programs. Between 2022 and 2025, the National Cancer Institute (NCI) funded supportive-care and cancer-related muscle wasting research grants totaling approximately USD 61 million, reorienting academic research pipelines toward mechanism-specific treatments rather than purely palliative approaches.

By region, North America holds the largest share of the Cancer Cachexia Market, at 40.1% of 2025 revenue, driven by National Comprehensive Cancer Network (NCCN) pathway integration. Europe holds the second-largest share, at 27.4%, driven by European Society for Clinical Nutrition and Metabolism (ESPEN) guideline adoption in tertiary care centers. Asia-Pacific is projected to grow at a CAGR of 5.67% through 2035, supported by China's National Reimbursement Drug List expanding supportive oncology coverage. Over the coming decade, the Cancer Cachexia Market is expected to transform from a palliative afterthought into a distinct therapeutic category with its own dedicated clinical trial infrastructure.

### Key Report Takeaways — Cancer Cachexia Market

### By Therapeutic Class

- Ghrelin receptor agonists captured 36.5% of the Cancer Cachexia Market share in 2025

### By Mechanism

- Catabolic-pathway inhibitors are advancing at a 7.08% CAGR through 2035
- Appetite stimulators generated USD 1.49 billion in 2025 revenue

### By Cancer Type

- Lung cancer accounted for 31.3% of demand in 2025
- Hematologic malignancies post the fastest expansion at 8.19% CAGR

### By Cancer Stage

- Pre-cachexia interventions grow at 8.06% CAGR as screening moves upstream

### By Region

- North America contributed 40.1% of Cancer Cachexia Market revenue in 2025
- Asia-Pacific records the quickest regional growth at 5.67% CAGR
- Europe delivered USD 0.83 Billion in 2025

## Market Size and Forecast (2021–2035)

Estimates blend bottom-up dispensing data from hospital and retail pharmacy channels across 32 countries with top-down triangulation against oncology supportive-care expenditure reported by national payers. Historical values were reconciled against manufacturer disclosures and public reimbursement databases; forecast years apply epidemiological incidence modelling layered onto observed treatment-penetration curves. The Cancer Cachexia Market series below is expressed in USD Billion at constant 2025 exchange rates.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Rising cancer incidence and survivorship | +0.82 pp | Global | Long-term (≥4 yr) | [8] |
| Ghrelin receptor agonist label expansion | +0.64 pp | Japan, US, EU | Medium-term (2–4 yr) | [1] |
| Regulatory recognition as distinct indication | +0.51 pp | US, EU, Japan | Medium-term (2–4 yr) | [2] |
| Biomarker-enabled patient identification | +0.47 pp | North America, Europe | Long-term (≥4 yr) | [7] |
| Payer reimbursement pilots | +0.39 pp | US, Japan, China | Short-term (≤2 yr) | [6] |
| Guideline integration into care pathways | +0.33 pp | Global | Short-term (≤2 yr) | [5] |
| Hospital pharmacy digitisation | +0.28 pp | Asia-Pacific | Medium-term (2–4 yr) | [9] |

### Ghrelin Receptor Agonist Momentum

Anamorelin's Japanese reimbursement covers non-small-cell lung, gastric, pancreatic, and colorectal cancers, and PMDA post-marketing surveillance across more than 3,400 patients reported lean body mass gains averaging 1.2 kg at 12 weeks [[1]](https://mhlw.go.jp). That evidence base has become the template for filings elsewhere. Sponsors in the United States and European Union are now designing bridging studies rather than starting from scratch.

### Regulatory Pathway Clarity

Ambiguity over acceptable endpoints stalled development for two decades. The FDA and international regulators have increasingly emphasized holistic clinical outcomes. At the same time, the European Medicines Agency (EMA) has advanced frameworks like its Future-proofing Qualification of Novel Methodologies (QoNM) action plan to streamline endpoint validation. Sponsors have responded with expanded clinical evaluation pipelines; interventional cachexia and muscle wasting trials registered on ClinicalTrials.gov have seen steady growth globally through mid-decade.

### Payer Pilots and Coverage

The Centers for Medicare & Medicaid Services integrated structured screening protocols within value-based frameworks like the Enhancing Oncology Model (EOM), which involves dozens of participating physician group practices and ties payment performance to supportive-care and total cost-of-care quality measures. Concurrently, China's National Healthcare Security Administration (NHSA) updated its National Reimbursement Drug List (NRDL) to incorporate major innovative oncology therapies, significantly driving down out-of-pocket patient financial burdens for advanced cancer treatments.

## Restraints

## Restraints Impact Analysis

Restraint weightings represent directional drag on compound growth and are modelled independently of the driver set. Negative values indicate the growth foregone relative to an unconstrained scenario; they are not additive against the headline forecast.

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Late-stage clinical trial attrition | −0.58 pp | Global | Long-term (≥4 yr) | [11] |
| Diagnostic under-recognition and coding gaps | −0.44 pp | Global | Medium-term (2–4 yr) | [13] |
| Payer reluctance on supportive-care agents | −0.37 pp | Europe | Medium-term (2–4 yr) | [14] |
| Low-cost off-label substitution | −0.31 pp | Asia-Pacific, South America | Short-term (≤2 yr) | [15] |
| Divergent endpoint definitions | −0.24 pp | Global | Long-term (≥4 yr) | [10] |

### Clinical Attrition Remains the Central Risk

Phase III programmes in this space have failed repeatedly. Analysis of registered trials shows roughly 68% of late-stage cachexia candidates terminated or missed primary endpoints between 2010 and 2024, largely because heterogeneous patient populations diluted treatment effect [[11]](https://clinicaltrials.gov). Every pipeline valuation in the Cancer Cachexia Market carries that discount.

### Patients Go Undiagnosed

Cachexia lacks a unique ICD-10 code in most reimbursement systems, so it is captured under generic malnutrition entries. A multicentre European audit found documented cachexia assessment in only 27% of eligible oncology admissions [[13]](https://espen.org). Untracked patients do not become treated patients.

### Payer Scepticism in Cost-Constrained Systems

England's NICE has historically applied full incremental cost-effectiveness thresholds to supportive-care agents without quality-of-life uplifts, and several European HTA bodies follow similar logic [[14]](https://nice.org.uk). Manufacturers must therefore generate function and hospitalisation data, which lengthens launch timelines by 12–18 months.

## Opportunities

## Cancer Cachexia Market Opportunities

### Upstream Screening and Pre-Cachexia Intervention

Treating patients before muscle loss becomes refractory changes the economics entirely. Pre-cachexia protocols expand at 8.06% CAGR, and health systems piloting routine screening at first oncology consultation report 19% fewer treatment interruptions [[13]](https://espen.org).

### Biomarker-Guided Precision Positioning

GDF-15 assays let sponsors enrich trial populations and let clinicians match mechanism to phenotype. Companies pairing a therapeutic with a companion diagnostic can defend premium pricing where undifferentiated agents cannot [[7]](https://onlinelibrary.wiley.com).

### Emerging Market Access Gaps

India, Brazil, and the ASEAN bloc together account for a large share of global cancer incidence yet under 8% of Cancer Cachexia Market revenue. Tiered pricing and local manufacturing partnerships open genuine white space, particularly where public tenders favour domestic supply [[16]](https://nha.gov.in).

### Digital Monitoring and Data Monetisation

Wearable-derived activity data and app-based dietary logging generate longitudinal evidence that payers increasingly demand. Vendors bundling remote monitoring with therapy create recurring-revenue models rather than one-off prescriptions [[9]](https://iqvia.com).

### Multimodal Care Bundles

Combining pharmacotherapy with structured exercise and dietary counselling produces stronger functional outcomes than any single arm. Integrated bundles priced as a service line give hospitals a reimbursable pathway and manufacturers a durable channel [[5]](https://esmo.org).

## Future Outlook

## Cancer Cachexia Market Future Outlook

### Mechanism Diversification

Ghrelin agonism will not hold its current concentration through 2035. Antibodies targeting GDF-15 and myostatin, plus dual anabolic-catabolic candidates, enter pivotal testing between 2027 and 2030 [[7]](https://onlinelibrary.wiley.com). Expect the Cancer Cachexia Market to fragment across three or four distinct mechanistic classes rather than consolidate.

### Algorithmic Risk Stratification

Health systems are embedding predictive models into oncology EMRs that flag weight-trajectory inflection points before clinicians notice them. Pilot deployments across 14 US academic centres improved early identification rates by roughly 34% [[9]](https://iqvia.com). Automated flagging converts a documentation problem into a treatment opportunity.

### Outcome-Linked Contracting

Payers will increasingly tie supportive-care reimbursement to measurable function and hospitalisation avoidance rather than prescription volume. Manufacturers with longitudinal real-world evidence gain contracting leverage; those without it face price erosion. The Cancer Cachexia Market shifts toward value-based agreements over the second half of the decade [[14]](https://nice.org.uk).

## Segment Insights

## Cancer Cachexia Market Segmentation

### By Therapeutic Class

Therapeutic class concentration in the Cancer Cachexia Market reflects where reimbursement exists rather than where science is most active.

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Ghrelin Receptor Agonists | 36.5% share | National reimbursement in Japan |
| Progestins (Megestrol Acetate) | USD 0.71 Billion | Low cost, broad availability |
| Corticosteroids | 4.02% CAGR | Short-course symptomatic use |
| Beta-Blockers / ACTAs | 6.81% CAGR | Emerging cardiometabolic evidence |
| Cannabinoids | USD 0.24 Billion | Appetite and nausea dual benefit |
| Other Therapeutic Classes | 8.9% share | Investigational and adjunct agents |

Ghrelin receptor agonists lead because anamorelin cleared a reimbursement hurdle no competitor has matched, and prescriber familiarity compounds annually. Progestins persist on price alone — megestrol acetate costs a fraction of branded alternatives and remains the default in tender-driven systems, though thromboembolic risk limits duration of use [[15]](https://thelancet.com).

### By Mechanism of Action

Mechanism segmentation reveals where Cancer Cachexia Market development capital is actually flowing.

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Appetite Stimulators | 49.2% share | Established prescribing habit |
| Anabolic Agents | USD 0.68 Billion | Lean mass preservation evidence |
| Anti-Inflammatory / Cytokine Modulators | 5.12% CAGR | Inflammation-driven phenotypes |
| Catabolic-Pathway Inhibitors | 7.08% CAGR | Next-generation pipeline depth |
| Combination / Multimodal Regimens | 6.9% share | Guideline endorsement |

Appetite stimulators dominate current revenue but face the clearest displacement risk, since increasing appetite without blocking muscle catabolism produces fat gain rather than functional improvement. Catabolic-pathway inhibitors grow fastest precisely because they address that gap, and several candidates now carry orphan designations tied to anorexia cachexia syndrome [[7]](https://onlinelibrary.wiley.com).

### By Cancer Type

Tumour-level demand within the Cancer Cachexia Market follows both prevalence and cachexia severity.

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Lung Cancer | 31.3% share | High incidence and cachexia prevalence |
| Pancreatic Cancer | USD 0.55 Billion | Severe wasting phenotype |
| Gastric & Colorectal Cancer | 4.61% CAGR | Surgical recovery optimisation |
| Head & Neck Cancer | 9.8% share | Swallowing impairment |
| Hematologic Malignancies | 8.19% CAGR | Transplant conditioning support |
| Other Cancer Types | USD 0.42 Billion | Broad supportive prescribing |

Lung cancer supplies the largest patient pool and carries anamorelin's original indication, so prescribing infrastructure already exists. Hematologic malignancies expand fastest as transplant and CAR-T centres formalise nutritional and anabolic protocols around conditioning regimens.

### By Stage of Cachexia

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Pre-Cachexia | 8.06% CAGR | Routine screening adoption |
| Cachexia (Established) | 51.4% share | Symptomatic presentation at diagnosis |
| Refractory Cachexia | USD 0.79 Billion | Palliative symptom management |

The Cachexia (Established) segment dominates the market with a 51.4% share driven by symptomatic presentation at diagnosis. The Pre-cachexia segment is identified as the fastest growing with an 8.06% CAGR driven by routine screening adoption. Refractory Cachexia accounts for USD 0.79 Billion driven by palliative symptom management.

### By Distribution Channel

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Hospital Pharmacies | 55.6% share | Specialist initiation protocols |
| Retail Pharmacies | USD 0.90 Billion | Chronic refill convenience |
| Online Pharmacies | 7.88% CAGR | Digital inventory and delivery |
| Specialty / Oncology Clinics | 6.3% share | Integrated care delivery |

Hospital Pharmacies dominate the distribution channel with a 55.6% share driven by specialist initiation protocols. Online Pharmacies represent the fastest-growing segment with a 7.88% CAGR driven by digital inventory and delivery. Retail Pharmacies account for USD 0.90 billion, and Specialty / Oncology Clinics hold a 6.3% share.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 40.1% share | Pathway integration, biomarker diagnostics |
| Europe | USD 0.83 Billion | HTA evidence generation, guideline rollout |
| Asia-Pacific | 5.67% CAGR (2026–2035) | Reimbursement expansion, local manufacturing |
| South America | 5.6% share | Public tender access, generic substitution |
| Middle East & Africa | USD 0.12 Billion | Tertiary oncology centre buildout |
| Total | USD 3.03 Billion | — |

Regional performance in the Cancer Cachexia Market tracks reimbursement maturity more closely than disease burden, which explains why Asia-Pacific outgrows its current revenue position.

### North America

| Country | Metric | Key Driver |
| --- | --- | --- |
| US | 84.6% of regional revenue | Enhancing Oncology Model quality measures |
| Canada | USD 0.11 Billion | Provincial cancer agency protocols |
| Mexico | 5.31% CAGR | IMSS oncology formulary expansion |

United States demand rests on NCCN Supportive Care pathway integration, which routed cachexia assessment into standard oncology workflow across more than 1,100 accredited programmes [[12]](https://cms.gov). Canadian provincial agencies fund multimodal clinics in Ontario and British Columbia. Mexico grows fastest as social security oncology coverage widens.

### Europe

| Country | Metric | Key Driver |
| --- | --- | --- |
| Germany | 23.4% of regional revenue | DRG supplements for nutrition teams |
| UK | USD 0.14 Billion | NHS Cancer Programme supportive care |
| France | 4.62% CAGR | INCa national cancer plan funding |
| Italy | 11.2% of regional revenue | Regional oncology network protocols |
| Spain | USD 0.07 Billion | SEOM guideline adoption |
| Nordic Countries | 4.18% CAGR | Registry-based outcome tracking |
| Russia | 5.1% of regional revenue | Federal oncology programme procurement |
| Rest of Europe | USD 0.09 Billion | Cross-border tertiary referral |

Germany anchors European volume because DRG coding permits supplementary reimbursement for hospital nutrition teams, giving cachexia management a funded home. France channels spending through INCa's national plan, which allocated roughly EUR 1.7 billion across 2021–2025 with supportive care as a named pillar [[17]](https://e-cancer.fr). Nordic registries supply the longitudinal outcome data that HTA bodies elsewhere still lack.

### Asia-Pacific

| Country | Metric | Key Driver |
| --- | --- | --- |
| Japan | 31.8% of regional revenue | Anamorelin national reimbursement |
| China | USD 0.19 Billion | NRDL supportive oncology listings |
| India | 6.94% CAGR | Ayushman Bharat oncology packages |
| South Korea | 9.6% of regional revenue | HIRA supportive care coverage |
| ASEAN | USD 0.06 Billion | Tertiary centre capacity growth |
| Rest of Asia-Pacific | 5.02% CAGR | Private oncology network expansion |

Japan remains the reference market for the Cancer Cachexia Market globally, since it was first to reimburse a mechanism-specific agent and now supplies the richest real-world dataset [[1]](https://mhlw.go.jp). China's NRDL negotiations cut list prices sharply but multiply treated volume. India grows quickest as Ayushman Bharat oncology packages reach district hospitals [[16]](https://nha.gov.in).

### South America

| Country | Metric | Key Driver |
| --- | --- | --- |
| Brazil | 52.7% of regional revenue | SUS oncology procurement |
| Argentina | USD 0.03 Billion | PAMI coverage for elderly patients |
| Rest of South America | 4.88% CAGR | Private insurance penetration |

Brazil dominates through SUS centralised procurement, which favours low-cost progestins but has begun tendering for newer agents following INCA protocol updates [[18]](https://inca.gov.br). Argentina's coverage concentrates in the elderly PAMI population. Regional growth depends heavily on currency stability and public health budget cycles.

### Middle East & Africa

| Country | Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 26.9% of regional revenue | Vision 2030 health sector transformation |
| UAE | USD 0.02 Billion | Private oncology centre density |
| South Africa | 5.44% CAGR | Public-private oncology partnerships |
| Egypt | 11.3% of regional revenue | National cancer institute network |
| Rest of MEA | USD 0.03 Billion | Referral to regional hubs |

Saudi Arabia leads regional spending as Vision 2030 funds new comprehensive cancer centres with integrated supportive care units [[19]](https://moh.gov.sa). South Africa expands fastest through public-private oncology partnerships. Access across much of the region still depends on patient travel to a handful of tertiary hubs.

## Competitive Benchmarking

## Competitive Benchmarking

Concentration sits in the medium band. Estimated HHI falls between 900 and 1,150, with the top five participants holding roughly 44–50% of revenue. Two structural features define competition: established pharmaceutical companies control commercialised assets. At the same time, clinical-stage biotechs own most of the differentiated pipeline, and nutrition specialists compete adjacent to pharmacotherapy rather than directly against it. Licensing rather than acquisition remains the dominant partnering mode in the Cancer Cachexia Market.

| Company | Est. Revenue Share Range | Key Offerings | Strategic Positioning |
| --- | --- | --- | --- |
| Helsinn Healthcare | ~13–17% | Anamorelin (ghrelin agonist) | First-mover with reimbursed asset |
| Pfizer Inc. | ~8–11% | Megestrol acetate portfolio, oncology supportive care | Scale and formulary reach |
| Abbott Laboratories | ~7–10% | Medical nutrition formulations | Adjacent nutrition franchise leader |
| Nestlé Health Science | ~6–9% | Oral supplements, clinical nutrition | Hospital and retail dual channel |
| Eli Lilly and Company | ~5–8% | Metabolic and anabolic pipeline | Leverages cardiometabolic expertise |
| Fresenius Kabi | ~4–7% | Parenteral and enteral nutrition | Institutional supply strength |
| Otsuka Holdings | ~4–6% | Supportive oncology agents, Japan | Deep domestic reimbursement access |
| Bristol Myers Squibb | ~3–5% | Immuno-oncology adjunct programmes | Combination positioning with IO backbone |
| Actimed Therapeutics | ~2–4% | ACTA candidate (S-pindolol) | Focused late-stage clinical asset |
| Veru Inc. | ~2–4% | Selective androgen receptor modulator | Muscle mass preservation focus |
| Artelo Biosciences | ~1–3% | Cannabinoid receptor agonist | Early-stage appetite mechanism |
| NGM Biopharmaceuticals | ~1–3% | GDF-15 pathway antibody | Biomarker-anchored differentiation |

Ranges are analyst estimates and do not sum precisely. Source: Market Research Future Analysis

## Recent News & Developments

## Recent News & Developments

- Helsinn Healthcare (March 2023): Reported five-year Japanese post-marketing data covering 3,400+ patients, strengthening the evidence dossier for filings in additional territories [[1]](https://mhlw.go.jp).
- US Food and Drug Administration (September 2023): Issued draft guidance defining acceptable endpoints for cancer-associated weight loss trials, unlocking stalled development programmes [[2]](https://fda.gov).
- Actimed Therapeutics (February 2024): Completed Phase IIa dosing for its beta-blocker-based candidate, reporting lean mass gains that supported progression to a larger study [[7]](https://onlinelibrary.wiley.com).
- European Medicines Agency (June 2024): Published a qualification opinion on physical function measures in oncology supportive care, aligning broadly with FDA thinking [[10]](https://ema.europa.eu).
- National Healthcare Security Administration, China (December 2024): Added supportive oncology agents to the reimbursement list, materially reducing patient cost share [[6]](https://nhsa.gov.cn).

- Centers for Medicare & Medicaid Services (October 2025): Expanded quality reporting within the Enhancing Oncology Model to include documented nutritional risk assessment [[12]](https://cms.gov).

## Frequently Asked Questions

**Q: How should investors screen early-stage assets in the Cancer Cachexia Market?**
A: Prioritise candidates with a defined biomarker enrichment strategy and a co-primary endpoint design matching current regulatory guidance. Assets lacking patient stratification carry disproportionate Phase III risk [7].

**Q: What do hospital formulary committees weigh most heavily when adding cachexia agents?**
A: Committees focus on functional outcome data and hospitalisation avoidance rather than weight gain alone. Budget impact modelling over 12 months usually decides borderline cases [14].

**Q: Does orphan drug designation apply in this indication?**
A: Designation is generally granted for tumour-specific cachexia subsets rather than the broad indication. Sponsors typically pursue it in pancreatic or head and neck populations where prevalence thresholds are met [11].

**Q: How does the Cancer Cachexia Market differ from broader supportive oncology in deal structure?**
A: Licensing dominates over acquisition here, with regional rights frequently split. Japanese and European partners often secure commercialisation separately from North American rights [21].

**Q: What integration challenges arise when adding cachexia screening to EMR workflows?**
A: Weight-trajectory calculations require longitudinal data that many oncology modules store inconsistently. Most deployments need custom flowsheet configuration and clinician training before flagging becomes reliable [9].

**Q: Which trial endpoints do regulators currently accept?**
A: Regulators favour co-primary designs combining body composition change with patient-reported physical function. Overall survival is not required, though it strengthens reimbursement negotiations [2][10].

**Q: Where does the Cancer Cachexia Market face the greatest generic erosion risk?**
A: Tender-driven systems in South America and parts of Asia-Pacific, where low-cost progestins and corticosteroids remain default therapy. Branded agents struggle to displace them without local pharmacoeconomic evidence [15].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/cancer-cachexia-market-11587*